Metastatic Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Description
Metastatic Colorectal Cancer Market Outlook
Thelansis’s “Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Metastatic Colorectal Cancer Overview
Metastatic colorectal cancer (mCRC), or Stage IV colorectal cancer, occurs when malignant cells originating in the colon or rectum spread to distant organs—most commonly the liver and lungs, and less frequently the peritoneum, brain, and bones. This metastatic progression is the primary driver of mortality in colorectal cancer.
While curative outcomes remain limited in advanced disease, therapeutic advancements have significantly improved overall survival and quality of life. Treatment is highly personalized and guided by tumor biology, molecular profile, and line of therapy, incorporating combinations of:
Chemotherapy (FOLFOX, FOLFIRI-based regimens)
Targeted therapies (EGFR inhibitors, VEGF inhibitors, BRAF inhibitors)
Immunotherapies (particularly in MSI-H/dMMR populations)
In select patients, metastasectomy and liver-directed therapies (ablation, embolization) play a critical role in disease control and potential long-term remission.
Key Highlights
mCRC represents a high-burden oncology segment, with a substantial proportion of colorectal cancer patients progressing to metastatic disease.
The drug-treatable patient population remains large and growing, supported by increasing diagnosis rates and improved survival outcomes.
Treatment paradigm is highly biomarker-driven, with segmentation based on: Tumor sidedness (left vs right) & Molecular status (RAS/BRAF mutations, MSI status)
RAS mutations account for 45–50% of patients, while BRAF mutations (8–10%) represent a smaller but high-risk subgroup.
Treatment is structured across multiple lines:
1st line: chemo + targeted therapy (EGFR/VEGF)
2nd line: therapy switch based on resistance patterns
3rd/4th line: later-line targeted agents and salvage therapies
Market Overview
The mCRC market is valued at $4.3Bn in 2025, projected to reach $6.1Bn by 2035, reflecting a CAGR of 3.5–4%.
Market growth is driven by: Increasing drug-treatable population (87K to 91K patients), Expanded use of targeted therapies and biologics, Improved treatment sequencing across multiple lines
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Thelansis’s “Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Metastatic Colorectal Cancer Overview
Metastatic colorectal cancer (mCRC), or Stage IV colorectal cancer, occurs when malignant cells originating in the colon or rectum spread to distant organs—most commonly the liver and lungs, and less frequently the peritoneum, brain, and bones. This metastatic progression is the primary driver of mortality in colorectal cancer.
While curative outcomes remain limited in advanced disease, therapeutic advancements have significantly improved overall survival and quality of life. Treatment is highly personalized and guided by tumor biology, molecular profile, and line of therapy, incorporating combinations of:
Chemotherapy (FOLFOX, FOLFIRI-based regimens)
Targeted therapies (EGFR inhibitors, VEGF inhibitors, BRAF inhibitors)
Immunotherapies (particularly in MSI-H/dMMR populations)
In select patients, metastasectomy and liver-directed therapies (ablation, embolization) play a critical role in disease control and potential long-term remission.
Key Highlights
mCRC represents a high-burden oncology segment, with a substantial proportion of colorectal cancer patients progressing to metastatic disease.
The drug-treatable patient population remains large and growing, supported by increasing diagnosis rates and improved survival outcomes.
Treatment paradigm is highly biomarker-driven, with segmentation based on: Tumor sidedness (left vs right) & Molecular status (RAS/BRAF mutations, MSI status)
RAS mutations account for 45–50% of patients, while BRAF mutations (8–10%) represent a smaller but high-risk subgroup.
Treatment is structured across multiple lines:
1st line: chemo + targeted therapy (EGFR/VEGF)
2nd line: therapy switch based on resistance patterns
3rd/4th line: later-line targeted agents and salvage therapies
Market Overview
The mCRC market is valued at $4.3Bn in 2025, projected to reach $6.1Bn by 2035, reflecting a CAGR of 3.5–4%.
Market growth is driven by: Increasing drug-treatable population (87K to 91K patients), Expanded use of targeted therapies and biologics, Improved treatment sequencing across multiple lines
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Table of Contents
157 Pages
- 1. Key Findings and Analyst Commentary
- 1.1 Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.
- 2. Disease Context
- 2.1 Disease definition, classification, etiology and pathophysiology, drug targets, etc.
- 3. Epidemiology
- 3.1 Key takeaways
- 3.2 Incidence / Prevalence
- 3.3 Diagnosed and Drug-Treated populations
- 3.4 Comorbidities
- 3.5 Other relevant patient segments
- 4. Market Size and Forecast
- 4.5 Key takeaways
- 4.6 Market drivers and constraints
- 4.7 Drug-class specific trends
- 4.8 Country-specific trends
- 5. Competitive Landscape
- 5.1 Current therapies
- 5.1.1 Key takeaways
- 5.1.2 Dx and Tx journey/algorithm
- 5.1.3 Key current therapies – profiles and KOL insights
- 5.2 Emerging therapies
- 5.2.1 Key takeaways
- 5.2.2 Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- 5.2.3 Notable early-phase pipeline
- 6. Unmet Need and TPP Analysis
- 6.1 Top unmet needs and future attainment by emerging therapies
- 6.2 TPP analysis and KOL expectations
- 7. Regulatory and Reimbursement Environments (by country and payer insights)
- 8. Appendix (e.g., bibliography, methodology)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
